CD8A and cancer: In both contexts, the trends match those of experimental observations—more aggressive treatments with more overall killing result from increasing CAR T-cell dose, intermediate CD4+:CD8+ ratio, increasing CAR-antigen affinity, and increasing cancer antigen density.